BNP Paribas Arbitrage SA Has $16.57 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)
BNP Paribas Arbitrage SA decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 22.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,992 shares of the pharmaceutical company’s stock after selling 30,900 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Vertex Pharmaceuticals were worth $16,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of VRTX. Jennison Associates LLC raised its holdings in Vertex Pharmaceuticals by 253.8% during the 2nd quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after acquiring an additional 3,626,368 shares during the period. Old Mutual Global Investors UK Ltd. raised its holdings in Vertex Pharmaceuticals by 1,384.7% during the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after acquiring an additional 1,114,939 shares during the period. Assenagon Asset Management S.A. raised its holdings in Vertex Pharmaceuticals by 9,422.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after acquiring an additional 883,998 shares during the period. AJO LP bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $71,956,000. Finally, Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after acquiring an additional 504,982 shares during the period. 92.79% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently weighed in on VRTX shares. Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. J P Morgan Chase & Co set a $184.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Raymond James Financial, Inc. raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 price target on the stock in a report on Wednesday, July 19th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, Vetr cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target on the stock. in a report on Monday, September 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the company. Vertex Pharmaceuticals has an average rating of “Buy” and an average price target of $173.15.
TRADEMARK VIOLATION WARNING: “BNP Paribas Arbitrage SA Has $16.57 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/bnp-paribas-arbitrage-sa-has-16-57-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Incorporated (VRTX) traded up $0.57 during trading on Monday, hitting $148.74. 861,000 shares of the stock were exchanged, compared to its average volume of 1,829,104. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $37,616.77, a price-to-earnings ratio of 247.90, a P/E/G ratio of 3.78 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. Vertex Pharmaceuticals’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.16 earnings per share. sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.72 earnings per share for the current year.
In related news, COO Ian F. Smith sold 75,000 shares of the stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $145.06, for a total value of $10,879,500.00. Following the completion of the transaction, the chief operating officer now directly owns 114,188 shares of the company’s stock, valued at $16,564,111.28. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Ian F. Smith sold 2,155 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $150.00, for a total transaction of $323,250.00. Following the completion of the transaction, the chief operating officer now directly owns 43,043 shares of the company’s stock, valued at $6,456,450. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 220,094 shares of company stock valued at $32,074,719. 1.80% of the stock is currently owned by company insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.